- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
- RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
- World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
Key statistics
As of last trade, RemeGen Co Ltd (9995:HKG) traded at 30.65, 104.88% above the 52 week low of 14.96 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.75 |
---|---|
High | 31.80 |
Low | 29.75 |
Bid | 30.50 |
Offer | 30.65 |
Previous close | 29.40 |
Average volume | 1.37m |
---|---|
Shares outstanding | 544.33m |
Free float | 305.21m |
P/E (TTM) | -- |
Market cap | 26.35bn HKD |
EPS (TTM) | -3.03 HKD |
Data delayed at least 15 minutes, as of Apr 25 2024 06:49 BST.
More ▼